Postoperative PainPhase 4NCT03650998
Transmuscular Quadratus Lumborum Block for Total Laparoscopic Hysterectomy.
A Phase 4 study testing Ropivacaine and Saline in people with Postoperative Pain, run by Zealand University Hospital at 1 site in Denmark.
Trial summary
Study is designed to assess the effect of the transmuscular quadratus lumborum block on postoperative opioid consumption and pain for patients undergoing laparoscopic hysterectomy. Study is randomized, placebo-controlled and blinded. Seventy patients will be included. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- Ropivacaine and Saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteDenmark
- Study dates
- 28 Sep 2018to 1 Dec 2019
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Scheduled for TLH
- Age ≥ 18 years at the date of inclusion Have received thorough information, orally and in written, and signed the "Informed Consent" form on participation in the trial
Who cannot join
- Inability to cooperate
- Inability to speak, read and understand Danish
- Allergy to local anaesthetics or opioids
- Daily intake of opioids, according to the investigators decision
- Local infection at the site of injection or systemic infection
- Difficulty visualisation of muscular and fascial structures in ultrasound visualisation necessary to the block administration
- Co-morbidity, ASA>3
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Zealand University Hospital, Department of Anaesthesiology
Roskilde, Region Sjælland, 4000
About this study
Official title: Ultrasound-guided Transmuscular Quadratus Lumborum Block for Laparoscopic Hysterectomy. A Double Blind, Randomized, Placebo Controlled Trial.
Study is designed to assess the effect of the transmuscular quadratus lumborum block on postoperative opioid consumption and pain for patients undergoing laparoscopic hysterectomy. Study is randomized, placebo-controlled and blinded. Seventy patients will be included.
Read the detailed description
Every year three hundred patients undergo hysterectomy at the department of obstetric and gynaecologic surgery at Zealand University Hospital, University of Copenhagen. The most common procedure is Total Laparoscopic Hysterectomy (TLH), which is the preferred technique in about four out of five hysterectomies at our facility. Multimodal analgesia consists of Paracetamol 1 g, Ibuprofen 400 mg and Dexamethasone 8 mg and Sufentanil 0.2 micrograms/kg for emergence if no contraindications are present. Standard general anaesthesia is total intravenous anaesthesia (TIVA) with an induction consisting of Remifentanil and Propofol infusions, a bolus of Propofol followed by muscle relaxation with Rocuronium. Patients are intubated in the trachea. Anaesthesia is maintained with Remifentanil and Propofol infusions and boluses of Rocuronium are administered whenever the surgeon requires it. Patients are always in Trendelenburg's position. Thirty minutes prior to emergence a bolus of Sufentanil 0.2 microg/kg is administered, as mentioned previously. Of interest: two other different opioid based regimens are currently used in the other two hospitals in Region Zealand where this procedure is performed. There is no national standards defined for dosages used for this kind of surgery. Additionally, no regional techniques are defined for this surgical procedure.
Our research group at Zealand University Hospital has conducted a thorough retrospective one-year survey for this patient group in order to define the quantity of the research problem. The electronic anaesthesia files, PACU files and ward files were meticulously reviewed. The survey revealed an accumulated morphine consumption in the first 12 postoperative hours of 44.1±30.8 mg of oral morphine equivalents in TLH patients. This dosage should be evaluated in relation to the standardized multimodal regimen described above.
Anaesthesiologists have primarily used either epidural catheters or long-lasting opioids as the basis for the postoperative pain management of expected or manifest moderate to severe pain. An epidural blockade can be contraindicated for some patients, and might cause bladder paralysis, lower extremity paralysis, hypotension etc. In addition, the epidural technique is labour-intensive in application as well as in its requirements for monitoring. Thus, the continuous epidural blockade is not a possibility of interest to the gynaecologists at our hospital. Therefore, until recently, opioids have been the sole treatment of pain, when over-the-counter medicine does not suffice. This presents a problem for the patients due to the well-known adverse effects of morphine including postoperative nausea and vomiting (PONV), itching, fatigue, constipation, confusion, respiratory depression and delayed mobilization.
Postoperative complications to surgery are more frequent in patients experiencing postoperative pain, and besides reducing the immediate postoperative pain perception, the investigators consider reduction of the total morphine consumption and the potential of reducing development of chronic pain through better treatment of the acute pain, as very interesting and promising for the patients in our study.
The investigators have the technical capability to improve perioperative pain management by taking advantage of USG peripheral nerve blocks (PNBs). The investigators' group of researchers have described the transmuscular quadratus lumborum (TQL) block and the mechanism by which the TQL block works has been proven in a major cadaveric study and some case reports.
The TQL block is applied with the patient in the lateral position, with the side to be blocked turned upwards. The ultrasound transducer is placed in the transverse position at the posterior axillary line, just above the iliac crest, and adjusted to visualize the QL and psoas major (PM) muscles and the transverse process of vertebrae L3 or L4. The needle is subsequently inserted at the posterolateral end of the transducer and advanced in plane. The needle is advanced through the QL muscle until the tip of the needle penetrates the investing fascia of the QL muscle. The local anaesthetic is then injected in the interfascial plane, but posterior to the transversalis fascia (TF) and between the QL and PM muscles. Confirmation of correct application can subsequently be visualized when the two muscles are seen to spread apart on the ultrasound image.
The investigators want to perform evidence-based research using the USG TQL for patients undergoing TLH. The hypothesis is that the USG TQL block administered bilaterally and applied pre-operatively in the PACU or in the theatre for the TLH patients can reduce the postoperative morphine consumption by 50 % during the first 12 postoperative hours. It is considered a block with very little discomfort for the patient.
All patients scheduled for a TLH will be screened according to the inclusion and exclusion criteria. The suitable candidates will be asked prior to surgery, whether they want to participate in the trial. If so, before elective TLH, the patient will receive the block, allocated in a randomised fashion to either active LA or placebo. The block will be performed under standard perioperative monitoring by a trained and skilled physician from the department of anaesthesia. The active treatment will be a bilateral TQL block with 30 mL Ropivacaine 0.375% on each side, whereas the placebo group will receive the same volume of isotonic Saline, applied in the exact same way. The patients will all receive the same multimodal analgesic regimens, consisting of 1 g Acetaminophen, 400 mg Ibuprofen and 8 mg of Dexamethasone prior to surgery, and a regimen of 3 x Ibuprofen and 4 x Acetaminophen a day until discharge. An IV Morphine Patient-Controlled Analgesia (PCA) - pump will be used for 24 hours after instructions are given and the pump is set to begin in the PACU. In order to keep the pooled administration of local anaesthetic below the accepted maximum recommended dosage, neither local anaesthetic infiltration performed by the surgeon nor supplemental rescue regional techniques will be performed. Whenever pain exceeds an NRS of three despite the primary use of the PCA pump, the PACU nurses will administer additional Morphine or Sufentanil as they already do by the present standards.
Aim:
The aim with this study is to investigate the efficacy of the USG TQL block vs. Placebo in patients undergoing TLH.
The hypothesis is that the bilateral TQL block will significantly reduce the opioid consumption during the first 12 postoperative hours and significantly reduce the Numerical Rating Scale (NRS) pain score (0-10/10) and opioid related side effects.
Outcome:
Primary outcome:
The primary outcome of the study will be:
Morphine consumption in the first 12 postoperative hours (data from PCA pump and the patient's medical record).
The secondary outcomes will be:
(A) Pain intensity (NRS 0-10/10) in the study period at T0 (arrival in the PACU), after 15, 30 and 45 minutes. And again at 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21 and 24 hours postoperatively. In addition, NRS score will be recorded electronically in relation to all morphine administrations, since all patients must enter their NRS pain score on the PCA pump display in relation to administration of the PCA boluses.
(B) Total morphine consumption. Morphine consumption at 3, 6, 9, 12, 18 and 24 postoperative hours.
(C) Duration of block (time to first opioid). (D) Patient satisfaction with application of the block. (E) The degree of morphine-related side effects (PONV, itching, fatigue, etc.). (F) Time from operation to ambulation. The investigators regard these outcome parameters as essential for the selected patient group, and it is the investigators' hope that this could lead to a better amelioration of postoperative pain and reduced morphine consumption postoperatively.
- Conditions
- Postoperative Pain
- Being tested
- Ropivacaine, Saline
- Keywords
- nerve block, ultrasound, opioids, hysterectomy
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RopivacaineDrug
See arm description
SalineDrug
See arm description
| Study group | Role | What they receive |
|---|---|---|
| Active | Active comparator | Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.
In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment. Receives: Drug: Ropivacaine |
| Placebo | Placebo comparator | Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.
In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment. Receives: Drug: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative opioid consumption
How much cumulated opioid in oral morphine equivalents does the participant require/use.
Measured: Twelve hours postoperatively
Secondary outcomes (1)
Postoperative pain intensity
NRS scale of 0-10.
Measured: 12 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Aug 2018
- Study start28 Sep 2018
- Primary completion1 Dec 2019
- Study completion1 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- More trials run by Zealand University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zealand University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jens Borglum, Ph.D.; MD, Study chair, Consultant, associate professor.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03650998
- Sponsor's protocol ID
- ZUH-TQL-TLH
- Status last verified
- Jan 2019
- First submitted
- 27 Aug 2018
- Last updated
- 13 Jan 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hansen C, Dam M, Nielsen MV, Tanggaard KB, Poulsen TD, Bendtsen TF, Borglum J. Transmuscular quadratus lumborum block for total laparoscopic hysterectomy: a double-blind, randomized, placebo-controlled trial. Reg Anesth Pain Med. 2021 Jan;46(1):25-30. doi: 10.1136/rapm-2020-101931. Epub 2020 Oct 20.
PubMed 33082286
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-guided Transmuscular Quadratus Lumborum Block for Laparoscopic Hysterectomy. A Double Blind, Randomized, Placebo Controlled Trial.
- ClinicalTrials.gov ID
- NCT03650998
- Acronym / sponsor ID
- ZUH-TQL-TLH
- Conditions
- Postoperative Pain
- Keywords
- nerve block, ultrasound, opioids, hysterectomy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Zealand University HospitalUniversity, hospital or other
- Study start
- 28 Sep 2018 (actual)
- Primary completion
- 1 Dec 2019 (actual)
- Study completion
- 1 Dec 2019 (actual)
- First posted
- 29 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study is designed to assess the effect of the transmuscular quadratus lumborum block on postoperative opioid consumption and pain for patients undergoing laparoscopic hysterectomy. Study is randomized, placebo-controlled and blinded. Seventy patients will be included.
Detailed description
Every year three hundred patients undergo hysterectomy at the department of obstetric and gynaecologic surgery at Zealand University Hospital, University of Copenhagen. The most common procedure is Total Laparoscopic Hysterectomy (TLH), which is the preferred technique in about four out of five hysterectomies at our facility. Multimodal analgesia consists of Paracetamol 1 g, Ibuprofen 400 mg and Dexamethasone 8 mg and Sufentanil 0.2 micrograms/kg for emergence if no contraindications are present. Standard general anaesthesia is total intravenous anaesthesia (TIVA) with an induction consisting of Remifentanil and Propofol infusions, a bolus of Propofol followed by muscle relaxation with Rocuronium. Patients are intubated in the trachea. Anaesthesia is maintained with Remifentanil and Propofol infusions and boluses of Rocuronium are administered whenever the surgeon requires it. Patients are always in Trendelenburg's position. Thirty minutes prior to emergence a bolus of Sufentanil 0.2 microg/kg is administered, as mentioned previously. Of interest: two other different opioid based regimens are currently used in the other two hospitals in Region Zealand where this procedure is performed. There is no national standards defined for dosages used for this kind of surgery. Additionally, no regional techniques are defined for this surgical procedure.
Our research group at Zealand University Hospital has conducted a thorough retrospective one-year survey for this patient group in order to define the quantity of the research problem. The electronic anaesthesia files, PACU files and ward files were meticulously reviewed. The survey revealed an accumulated morphine consumption in the first 12 postoperative hours of 44.1±30.8 mg of oral morphine equivalents in TLH patients. This dosage should be evaluated in relation to the standardized multimodal regimen described above.
Anaesthesiologists have primarily used either epidural catheters or long-lasting opioids as the basis for the postoperative pain management of expected or manifest moderate to severe pain. An epidural blockade can be contraindicated for some patients, and might cause bladder paralysis, lower extremity paralysis, hypotension etc. In addition, the epidural technique is labour-intensive in application as well as in its requirements for monitoring. Thus, the continuous epidural blockade is not a possibility of interest to the gynaecologists at our hospital. Therefore, until recently, opioids have been the sole treatment of pain, when over-the-counter medicine does not suffice. This presents a problem for the patients due to the well-known adverse effects of morphine including postoperative nausea and vomiting (PONV), itching, fatigue, constipation, confusion, respiratory depression and delayed mobilization.
Postoperative complications to surgery are more frequent in patients experiencing postoperative pain, and besides reducing the immediate postoperative pain perception, the investigators consider reduction of the total morphine consumption and the potential of reducing development of chronic pain through better treatment of the acute pain, as very interesting and promising for the patients in our study.
The investigators have the technical capability to improve perioperative pain management by taking advantage of USG peripheral nerve blocks (PNBs). The investigators' group of researchers have described the transmuscular quadratus lumborum (TQL) block and the mechanism by which the TQL block works has been proven in a major cadaveric study and some case reports.
The TQL block is applied with the patient in the lateral position, with the side to be blocked turned upwards. The ultrasound transducer is placed in the transverse position at the posterior axillary line, just above the iliac crest, and adjusted to visualize the QL and psoas major (PM) muscles and the transverse process of vertebrae L3 or L4. The needle is subsequently inserted at the posterolateral end of the transducer and advanced in plane. The needle is advanced through the QL muscle until the tip of the needle penetrates the investing fascia of the QL muscle. The local anaesthetic is then injected in the interfascial plane, but posterior to the transversalis fascia (TF) and between the QL and PM muscles. Confirmation of correct application can subsequently be visualized when the two muscles are seen to spread apart on the ultrasound image.
The investigators want to perform evidence-based research using the USG TQL for patients undergoing TLH. The hypothesis is that the USG TQL block administered bilaterally and applied pre-operatively in the PACU or in the theatre for the TLH patients can reduce the postoperative morphine consumption by 50 % during the first 12 postoperative hours. It is considered a block with very little discomfort for the patient.
All patients scheduled for a TLH will be screened according to the inclusion and exclusion criteria. The suitable candidates will be asked prior to surgery, whether they want to participate in the trial. If so, before elective TLH, the patient will receive the block, allocated in a randomised fashion to either active LA or placebo. The block will be performed under standard perioperative monitoring by a trained and skilled physician from the department of anaesthesia. The active treatment will be a bilateral TQL block with 30 mL Ropivacaine 0.375% on each side, whereas the placebo group will receive the same volume of isotonic Saline, applied in the exact same way. The patients will all receive the same multimodal analgesic regimens, consisting of 1 g Acetaminophen, 400 mg Ibuprofen and 8 mg of Dexamethasone prior to surgery, and a regimen of 3 x Ibuprofen and 4 x Acetaminophen a day until discharge. An IV Morphine Patient-Controlled Analgesia (PCA) - pump will be used for 24 hours after instructions are given and the pump is set to begin in the PACU. In order to keep the pooled administration of local anaesthetic below the accepted maximum recommended dosage, neither local anaesthetic infiltration performed by the surgeon nor supplemental rescue regional techniques will be performed. Whenever pain exceeds an NRS of three despite the primary use of the PCA pump, the PACU nurses will administer additional Morphine or Sufentanil as they already do by the present standards.
Aim:
The aim with this study is to investigate the efficacy of the USG TQL block vs. Placebo in patients undergoing TLH.
The hypothesis is that the bilateral TQL block will significantly reduce the opioid consumption during the first 12 postoperative hours and significantly reduce the Numerical Rating Scale (NRS) pain score (0-10/10) and opioid related side effects.
Outcome:
Primary outcome:
The primary outcome of the study will be:
Morphine consumption in the first 12 postoperative hours (data from PCA pump and the patient's medical record).
The secondary outcomes will be:
(A) Pain intensity (NRS 0-10/10) in the study period at T0 (arrival in the PACU), after 15, 30 and 45 minutes. And again at 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21 and 24 hours postoperatively. In addition, NRS score will be recorded electronically in relation to all morphine administrations, since all patients must enter their NRS pain score on the PCA pump display in relation to administration of the PCA boluses.
(B) Total morphine consumption. Morphine consumption at 3, 6, 9, 12, 18 and 24 postoperative hours.
(C) Duration of block (time to first opioid). (D) Patient satisfaction with application of the block. (E) The degree of morphine-related side effects (PONV, itching, fatigue, etc.). (F) Time from operation to ambulation. The investigators regard these outcome parameters as essential for the selected patient group, and it is the investigators' hope that this could lead to a better amelioration of postoperative pain and reduced morphine consumption postoperatively.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active | Active comparator | Drug: RopivacaineActive bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot. In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment. |
| Placebo | Placebo comparator | Drug: SalinePlacebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot. In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Scheduled for TLH
- Age ≥ 18 years at the date of inclusion Have received thorough information, orally and in written, and signed the "Informed Consent" form on participation in the trial
Key exclusion criteria (7 listed)
- Inability to cooperate
- Inability to speak, read and understand Danish
- Allergy to local anaesthetics or opioids
- Daily intake of opioids, according to the investigators decision
- Local infection at the site of injection or systemic infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RopivacaineSee arm description | Drug | Active |
| SalineSee arm description | Drug | Placebo |
Primary outcome
Postoperative opioid consumption
Time frame: Twelve hours postoperatively
How much cumulated opioid in oral morphine equivalents does the participant require/use.
1 secondary outcome
Postoperative pain intensity
Time frame: 12 hours.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2020.
- Derived from this study: PubMed 33082286Hansen C, Dam M, Nielsen MV, Tanggaard KB, Poulsen TD, Bendtsen TF, Borglum J. Transmuscular quadratus lumborum block for total laparoscopic hysterectomy: a double-blind, randomized, placebo-controlled trial. Reg Anesth Pain Med. 2021 Jan;46(1):25-30. doi: 10.1136/rapm-2020-101931. Epub 2020 Oct 20.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jens Borglum, Ph.D.; MD study chair
Consultant, associate professor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ropivacaine and Saline in people with Postoperative Pain, run by Zealand University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative opioid consumption (time frame: Twelve hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03650998, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2020.